INDV
ACHAT TOTAL: 1500 titres (~54420 USD) VENTE TOTALE: 18586 titres (~764628 USD)
- Insiders
- Anderson Woodrow D, Heidbreder Christian
- Total bought
- $54,420
- Total sold
- $764,628
- Last activity
- 2026-08-05
- Last synced
-
2026-08-09 12:58:10
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-31
INDV presents a mixed profile: a moderate catalyst (MA_RUMOR with an all-stock merger + Q2 beat) is partially offset by fragile liquidity fundamentals (current ratio 0.71, negative working capital) and meaningful deal…
The first sentence of the analysis written for INDV on 2026-08-31 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 80.1% | 80.6% | 84.1% | 83.2% | 83.9% | |
| Ebit Margin | 22.9% | 4.6% | -10.4% | -6.9% | 27.3% | |
| Ebitda Margin | 24.5% | 7.1% | -9.1% | -5.1% | 30.1% | |
| Operating Profit Margin | 21.4% | 2.7% | -14.3% | -9.0% | 26.9% | |
| Pretax Profit Margin | 19.3% | 1.2% | -13.6% | -9.9% | 24.0% | |
| Continuous Operations Profit Margin | 16.9% | 0.3% | -11.8% | -5.0% | 25.9% | |
| Net Profit Margin | 16.9% | 0.2% | -11.8% | -4.9% | 25.9% | |
| Bottom Line Profit Margin | 16.9% | 0.2% | -11.8% | -4.9% | 25.9% | |
| Current Ratio | 0.713 | 0.894 | 0.981 | 1.236 | 1.796 | |
| Quick Ratio | 0.546 | 0.704 | 0.877 | 1.124 | 1.678 | |
| Solvency Ratio | 0.177 | 0.019 | -0.058 | -0.016 | 0.139 | |
| Cash Ratio | 0.213 | 0.340 | 0.245 | 0.760 | 1.371 | |
| Price To Earnings Ratio | 21.357 | 823.179 | 1,045.890 | -58.784 | 12.500 | |
| Price To Earnings Growth Ratio | 0.002 | 240.368 | -10.062 | 0.464 | -0.055 | |
| Forward Price To Earnings Growth Ratio | 0.002 | 240.368 | -10.062 | 0.464 | -0.055 | |
| Price To Earnings Diluted Ratio | 21.878 | 828.667 | 1,082.979 | -58.784 | 13.168 | |
| Price To Earnings Diluted Growth Ratio | 0.002 | 129.824 | -10.432 | 0.458 | -0.060 | |
| Price To Book Ratio | -45.765 | -4.715 | -10.977 | 58.966 | 12.377 | |
| Price To Sales Ratio | 3.620 | 1.381 | 1.918 | 3.356 | 3.177 | |
| Price To Free Cash Flow Ratio | -47.713 | 328.152 | -5.940 | -335.946 | 7.877 | |
| Price To Operating Cash Flow Ratio | -166.111 | 45.577 | -6.989 | -755.878 | 7.118 | |
| Debt To Assets Ratio | 0.292 | 0.284 | 0.160 | 0.156 | 0.156 | |
| Debt To Equity Ratio | -3.582 | -1.078 | -1.482 | 5.402 | 1.409 | |
| Debt To Capital Ratio | 1.387 | 13.889 | 3.076 | 0.844 | 0.585 | |
| Long Term Debt To Capital Ratio | 1.510 | -9.545 | 5.152 | 0.822 | 0.541 | |
| Financial Leverage Ratio | -12.286 | -3.790 | -9.241 | 34.686 | 9.025 | |
| Working Capital Turnover Ratio | -6.845 | -19.161 | 10.060 | 2.045 | 1.288 | |
| Operating Cash Flow Ratio | -0.030 | 0.038 | -0.233 | -0.004 | 0.439 | |
| Operating Cash Flow Sales Ratio | -0.022 | 0.030 | -0.274 | -0.004 | 0.446 | |
| Free Cash Flow Operating Cash Flow Ratio | 3.481 | 0.139 | 1.177 | 2.250 | 0.904 | |
| Debt Service Coverage Ratio | 3.274 | 1.237 | -1.681 | -0.062 | 8.724 | |
| Interest Coverage Ratio | 5.889 | 0.780 | -4.457 | -2.793 | 8.192 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.692 | 2.000 | -25.000 | -1.333 | 117.667 | |
| Operating Cash Flow Coverage Ratio | -0.077 | 0.096 | -1.060 | -0.014 | 1.234 | |
| Capital Expenditure Coverage Ratio | -0.403 | 1.161 | -5.660 | -0.800 | 10.382 | |
| Dividend Paid And Capex Coverage Ratio | -0.403 | 1.161 | -5.660 | -0.800 | 10.382 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.266 | 20.200 | -20.845 | -54.833 | 7.129 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 80.2% | ▼-0.4% | ▼-2.2% |
| Ebit Margin | 22.9% | ▲18.3% | ▲15.4% |
| Ebitda Margin | 24.5% | ▲17.5% | ▲15.0% |
| Operating Profit Margin | 21.4% | ▲18.7% | ▲15.8% |
| Pretax Profit Margin | 19.3% | ▲18.1% | ▲15.1% |
| Continuous Operations Profit Margin | 17.0% | ▲16.7% | ▲11.7% |
| Net Profit Margin | 17.0% | ▲16.8% | ▲11.7% |
| Bottom Line Profit Margin | 17.0% | ▲16.8% | ▲11.7% |
| Current Ratio | 0.713 | ▼-0.180 | ▼-0.411 |
| Quick Ratio | 0.546 | ▼-0.158 | ▼-0.440 |
| Solvency Ratio | 0.177 | ▲0.158 | ▲0.125 |
| Cash Ratio | 0.213 | ▼-0.126 | ▼-0.372 |
| Price To Earnings Ratio | 21.357 | ▼-801.822 | ▼-347.471 |
| Price To Earnings Growth Ratio | 0.002 | ▼-240.366 | ▼-46.142 |
| Forward Price To Earnings Growth Ratio | 0.002 | ▼-240.366 | ▼-46.142 |
| Price To Earnings Diluted Ratio | 21.878 | ▼-806.789 | ▼-355.704 |
| Price To Earnings Diluted Growth Ratio | 0.002 | ▼-129.822 | ▼-23.957 |
| Price To Book Ratio | -45.765 | ▼-41.050 | ▼-47.742 |
| Price To Sales Ratio | 3.620 | ▲2.239 | ▲0.930 |
| Price To Free Cash Flow Ratio | -47.713 | ▼-375.865 | ▼-36.999 |
| Price To Operating Cash Flow Ratio | -166.111 | ▼-211.688 | ▲9.146 |
| Debt To Assets Ratio | 0.291 | ▲0.007 | ▲0.082 |
| Debt To Equity Ratio | -3.582 | ▼-2.504 | ▼-3.716 |
| Debt To Capital Ratio | 1.387 | ▼-12.502 | ▼-2.569 |
| Long Term Debt To Capital Ratio | 1.510 | ▲11.056 | ▲1.814 |
| Financial Leverage Ratio | -12.286 | ▼-8.495 | ▼-15.964 |
| Working Capital Turnover Ratio | -6.845 | ▲12.316 | ▼-4.323 |
| Operating Cash Flow Ratio | -0.029 | ▼-0.068 | ▼-0.072 |
| Operating Cash Flow Sales Ratio | -0.022 | ▼-0.052 | ▼-0.057 |
| Free Cash Flow Operating Cash Flow Ratio | 3.482 | ▲3.343 | ▲1.891 |
| Debt Service Coverage Ratio | 3.274 | ▲2.037 | ▲0.975 |
| Interest Coverage Ratio | 5.889 | ▲5.108 | ▲4.367 |
| Short Term Operating Cash Flow Coverage Ratio | -0.692 | ▼-2.692 | ▼-19.221 |
| Operating Cash Flow Coverage Ratio | -0.077 | ▼-0.173 | ▼-0.113 |
| Capital Expenditure Coverage Ratio | -0.403 | ▼-1.564 | ▼-1.339 |
| Dividend Paid And Capex Coverage Ratio | -0.403 | ▼-1.564 | ▼-1.339 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.266 | ▼-4.933 | ▲21.883 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.49B | $1.64B | $2.10B | $3.02B | $2.51B | |
| Enterprise value | $4.64B | $1.70B | $2.06B | $2.52B | $1.70B | |
| EV / Sales | 3.75x | 1.43x | 1.89x | 2.80x | 2.15x | |
| EV / Op. cash flow | -171.89x | 47.13x | -6.88x | -630.58x | 4.81x | |
| EV / Free cash flow | -49.37x | 339.35x | -5.85x | -280.26x | 5.32x | |
| EV / EBITDA | 15.27x | 20.20x | -20.84x | -54.83x | 7.13x | |
| Net debt / EBITDA | 0.51x | 0.67x | 0.33x | 10.89x | -3.43x | |
| Current ratio | 0.71x | 0.89x | 0.98x | 1.24x | 1.80x | |
| Income quality | -0.13x | 5.14x | 2.38x | 0.09x | 1.66x | |
| Graham number | — | — | — | — | $7 | |
| Graham net-net | -$7 | -$8 | -$9 | -$4 | -$2 | |
| Tax burden | 87.9% | 14.3% | 86.6% | 49.4% | 107.9% | |
| Interest burden | 84.2% | 25.5% | 130.7% | 143.5% | 88.0% | |
| Working capital | -$262.0M | -$100.0M | -$24.0M | $241.3M | $640.0M | |
| Invested capital | -$90.0M | $46.0M | $113.0M | $396.8M | $817.0M | |
| Return on assets | 17.4% | 0.2% | -7.3% | -2.5% | 11.2% | |
| Operating ROA | 21.0% | 2.1% | -8.8% | -4.5% | 12.7% | |
| Return on tangible assets | 17.5% | 0.2% | -7.4% | -2.6% | 11.7% | |
| Return on equity | -214.3% | -0.6% | 67.5% | -85.8% | 101.0% | |
| Return on invested capital | 70.8% | 1.7% | -27.7% | -5.4% | 20.5% | |
| Return on capital employed | 91.4% | 8.4% | -32.8% | -10.7% | 20.7% | |
| Earnings yield | 4.7% | 0.1% | -6.2% | -1.5% | 8.2% | |
| Free cash flow yield | -2.1% | 0.3% | -16.8% | -0.3% | 12.7% | |
| Capex / Op. cash flow | -248.1% | 86.1% | -17.7% | -125.0% | 9.6% | |
| Capex / Depreciation | 335.0% | 110.7% | 353.3% | 31.3% | 154.5% | |
| Capex / Sales | 5.4% | 2.6% | 4.8% | 0.6% | 4.3% | |
| SG&A / Sales | 51.2% | 52.0% | 52.1% | 52.1% | 54.5% | |
| R&D / Sales | 7.8% | 9.0% | 10.6% | 8.2% | 6.6% | |
| Stock comp / Sales | 2.1% | 2.0% | 1.9% | 1.8% | 1.4% | |
| Intangibles / Total assets | 0.2% | 0.5% | 0.7% | 3.9% | 4.5% | |
| Days sales outstanding | 75d | 78d | 85d | 89d | 93d | |
| Days payables outstanding | 71d | 100d | 82d | 80d | 75d | |
| Operating cycle | 302d | 359d | 368d | 366d | 366d | |
| Cash conversion cycle | 231d | 260d | 286d | 286d | 292d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+173.3%EV / Sales ▲+162.3%EV / EBITDA ▼-24.4%EV / Op. cash flow ▼-219.021Earnings yield ▲+0.046
Profitability
Return on equity ▼-2.137Return on assets ▲+0.173Return on invested capital ▲+0.691Return on capital employed ▲+0.830Operating ROA ▲+0.189Income quality ▼-5.271Tax burden ▲+0.736
Efficiency
Days sales outstanding ▼-2.918Days payables outstanding ▼-28.326Operating cycle ▼-57.161Cash conversion cycle ▼-28.835Capex / Sales ▲+0.028R&D / Sales ▼-0.012
Balance-sheet strength
Current ratio ▼-0.180Net debt / EBITDA ▼-0.154Working capital ▼-162000000.000Invested capital ▼-136000000.000Intangibles / Total assets ▼-0.004
Change over 5 years
Valuation
Market cap ▲+78.5%EV / Sales ▲+74.6%EV / EBITDA ▲+114.2%EV / Op. cash flow ▼-176.695Earnings yield ▼-0.035
Profitability
Return on equity ▼-3.153Return on assets ▲+0.063Return on invested capital ▲+0.503Return on capital employed ▲+0.707Operating ROA ▲+0.083Income quality ▼-1.786Tax burden ▼-0.200
Efficiency
Days sales outstanding ▼-18.090Days payables outstanding ▼-3.505Operating cycle ▼-64.109Cash conversion cycle ▼-60.604Capex / Sales ▲+0.011R&D / Sales ▲+0.013
Balance-sheet strength
Current ratio ▼-1.083Net debt / EBITDA ▲+3.942Working capital ▼-902000000.000Invested capital ▼-907000000.000Intangibles / Total assets ▼-0.043
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-07 Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
- 2026-08-07 Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.
- 2026-08-04 INDV to Merge With Supernus, Beats on Q2 Earnings, Raises ''26 Outlook Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
- 2026-08-03 $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) PR Newsw
- 2026-08-03 $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Indivior Pharmaceuticals, Inc. (NASDAQ: INDV ) related to its merger with Supernus Pharmaceuticals, Inc. Upon closing of the proposed transaction, Indivior shareholders will own approximately 56.5% of the combined company.
- 2026-08-03 Supernus Pharmaceuticals (SUPN) Announces Transformative Merger with Indivior (INDV) Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock merger with Indivior (INDV). This strategic move comes alongs
- 2026-08-03 Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmaceutical company.
- 2026-08-03 INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages Indivior shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersa.
- 2026-08-03 Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.51 per share a year ago.
- 2026-08-03 Supernus, Indivior merge to strengthen neuroscience drug portfolio Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.